CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Résumé de cet Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhir, S.
Right arrow Articles by Athwal, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhir, S.
Right arrow Articles by Athwal, G. S.
Canadian Journal of Anesthesia 54:912-916 (2007)
© Canadian Anesthesiologists' Society, 2007

Case Reports/Case Series

Case report: Ropivacaine neurotoxicity at clinical doses in interscalene brachial plexus block

[Présentation de cas : neurotoxicité de la ropivacaïne à des doses cliniques lors du bloc du plexus brachial par approche interscalénique]

Shalini Dhir, MBBS MD*, Sugantha Ganapathy, FRCPC*, Peter Lindsay, FRCPC* and George S. Athwal, FRCPC{dagger}

* From the Departments of Anesthesia and Perioperative Medicine, and
{dagger} Orthopedic Surgery, University of Western Ontario, London, Ontario, Canada.

Address correspondence to: Dr. Shalini Dhir, 268 Grosvenor Street, London, Ontario N6A 5V5, Canada. Phone: 519-646-6000, ext: 64505; Fax: 519-646-6016; E-mail: sdhir2{at}uwo.ca

Purpose: To describe a case of ropivacaine toxicity following an ultrasound guided interscalene block and discuss the possible mechanisms involved.

Clinical features: A 76-yr-old woman with multiple myeloma was scheduled for open reduction and internal fixation following a pathological fracture of her left upper humerus. She developed central nervous system toxicity with ropivacaine 15 min after a carefully placed ultrasound-guided interscalene catheter. The dose of ropivacaine was within recommended limits and there was no evidence that the catheter was intravascular. Surgery proceeded uneventfully under general anesthesia. The interscalene catheter was left in situ for postoperative evaluation and intravascular injection was ruled out with a colour Doppler study. The total ropivacaine plasma concentration was 3.68 µg·mL–1. Neurological evaluation, contrast computerized tomography and electroencephalogram were normal. The patient was discharged home with no sequelae. Advanced age, malnutrition, epinephrine and possible elevation of {alpha}-1-acid glycoprotein levels could have altered the pharmacokinetics of plasma ropivacaine and possibly contributed to delayed neurotoxicity.

Conclusions: Local anesthetic toxicity is an uncommon but well documented complication of regional anesthesia. Careful monitoring and preparedness for managing complications during the conduct of regional anesthesia cannot be overemphasized. Experience from this case suggests that local anesthesia toxicity can happen within safe dose limits and without intravascular placement despite careful attention to needle and catheter placement, fractionated dosing and frequent aspirations.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Canadian Anesthesiologists' Society.